Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This represents a 43.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amy Bachrodt also recently made the following trade(s):

• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total value of $200,400.00.

Maze Therapeutics Stock Up 3.4%

Shares of NASDAQ:MAZE opened at $41.43 on Friday. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $43.29. The stock has a market cap of $1.99 billion and a price-to-earnings ratio of -1.98. The business has a 50-day moving average price of $36.81 and a 200-day moving average price of $24.70.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analysts have been raising ratings and targets (consensus remains a “Buy”, average PT ≈ $43.38), supporting upside expectations. Analyst Ratings/Targets
• Positive Sentiment: Several institutions have increased or initiated stakes (e.g., Vanguard, Frazier, ARCH, Marshall Wace), indicating institutional interest that can underpin the stock. Institutional Ownership Details
• Neutral Sentiment: Recent Q3/Q4 results showed an EPS beat (reported -$0.66 vs. -$0.74 consensus), which is supportive but the company remains unprofitable and clinical-stage. Earnings Summary
• Neutral Sentiment: A de‑minimis sale of 100 shares by insider Atul Dandekar (Dec. 30) is immaterial on its own. Small Form 4
• Negative Sentiment: Atul Dandekar sold 72,400 shares (~$2.94M at ~$40.56) and reduced his stake by ~87.3% — the largest and most sentiment‑negative transaction reported. Dandekar Form 4
• Negative Sentiment: CMO Harold Bernstein sold 45,000 shares (~$1.83M at ~$40.56). Large C‑suite sales can raise questions on insider conviction and add selling pressure. Bernstein Form 4
• Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (~$606K combined; sales at ~$40.58 and ~$40.08), materially reducing her stake. Multiple insider sales may weigh on near‑term sentiment. Bachrodt Form 4

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. CWM LLC purchased a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. raised its holdings in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the period. Corebridge Financial Inc. acquired a new position in Maze Therapeutics in the 1st quarter worth about $48,000. Russell Investments Group Ltd. boosted its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the third quarter valued at approximately $52,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MAZE shares. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price for the company. Guggenheim reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. Wedbush boosted their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Finally, Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $43.38.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.